{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:05:42Z","timestamp":1773335142474,"version":"3.50.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Petasites hybridus<\/jats:italic>\n                      is a plant from the\n                      <jats:italic>Asteraceae<\/jats:italic>\n                      family used in migraine prophylaxis. Petasins and isopetasins, one of its constituents, act through antinociceptive, anti-CGRP, anti-inflammatory mechanisms and on calcium channels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      This study aimed to evaluate the therapeutic efficacy of\n                      <jats:italic>Petasites hybridus<\/jats:italic>\n                      in the prophylaxis of episodic migraine (EM) and chronic migraine (CM).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was a single-center, retrospective, observational, uncontrolled, descriptive, and real-world study with 120 consecutive patients with EM or CM treated with\n                      <jats:italic>Petasites hybridus<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One hundred and twenty patients (72 with EM and 48 with CM) were treated with\n                      <jats:italic>Petasites hybridus<\/jats:italic>\n                      , whose mean age was 35.4\u202f\u00b1\u202f12.4\u202fyears, ranging from 18 to 60\u202fyears. Before treatment, the average frequency of headache for EM and CM was 6.0\u202f\u00b1\u202f2.7 and 26.3\u202f\u00b1\u202f5.1\u202fdays per month, respectively. After 12\u202fweeks, there was a reduction in the number of days with headache, both in the EM and CM, respectively, to 2.6\u202f\u00b1\u202f2.9 and 12.7\u202f\u00b1\u202f8.6 (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.0001). The reduction in headache attacks was greater than 50% in 59.2% of patients. There was a reduction in disability in both groups. Adverse events occurred in 28.3% of patients, including a bitter sensation in the mouth and\/or eructation, lasting 6.4\u202f\u00b1\u202f2.7\u202fdays and ranging from 2 to 14\u202fdays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Petasites hybridus<\/jats:italic>\n                      was well tolerated and reduced the number of headache days per month by \u226550% in 60% of migraine patients within the first 12\u202fweeks, providing a reduction in the degree of disability. Furthermore,\n                      <jats:italic>Petasites hybridus<\/jats:italic>\n                      (Petamig\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) is free of pyrrolizidine alkaloids, making it appropriate and safe for prescription to patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1784624","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:27:48Z","timestamp":1773293268000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Petasites hybridus in migraine prophylaxis: the first real-world study"],"prefix":"10.3389","volume":"17","author":[{"given":"Raimundo Pereira","family":"Silva-N\u00e9to","sequence":"first","affiliation":[{"name":"Department of Neurology, Federal University of the Parna\u00edba Delta","place":["Parna\u00edba, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1055\/s-0042-1756441","article-title":"Consensus of the Brazilian Headache Society (SBCe) for the prophylactic treatment of episodic migraine: part I","volume":"80","author":"Melhado","year":"2022","journal-title":"Arq Neuropsiquiatr"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3331024251387721","DOI":"10.1177\/03331024251387721","article-title":"Early treatment in migraine\u2014a call to shift prevention from attacks to disease progression: a position statement from the International Headache Society","volume":"45","author":"Pozo-Rosich","year":"2025","journal-title":"Cephalalgia"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice","volume":"61","author":"Ailani","year":"2021","journal-title":"Headache"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","article-title":"Diagnosis and management of migraine in ten steps","volume":"17","author":"Eigenbrodt","year":"2021","journal-title":"Nat Rev Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1526-4610.2005.4501001.x","article-title":"Migraine: epidemiology, impact and risk factors for progression","volume":"45","author":"Lipton","year":"2005","journal-title":"Headache"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/s0006-2952(01)00552-4","article-title":"Role of petasin in the potential anti-inflammatory activity of a plant extract of Petasites hybridus","volume":"61","author":"Thomet","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1055\/s-2006-959492","article-title":"Identification and characterization of inhibitors of peptide-leukotriene-synthesis from Petasites hybridus","volume":"60","author":"Bickel","year":"1994","journal-title":"Planta Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.5414\/CPP38430","article-title":"An extract of Petasites hybridus is effective in the prophylaxis of migraine","volume":"38","author":"Grossmann","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000076535","article-title":"The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria","volume":"51","author":"Diener","year":"2004","journal-title":"Eur Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1212\/01.wnl.0000147290.68260.11","article-title":"Petasites hybridus root (butterbur) is an effective preventive treatment for migraine","volume":"63","author":"Lipton","year":"2004","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/j.1526-4610.2005.05044.x","article-title":"Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract","volume":"45","author":"Pothmann","year":"2005","journal-title":"Headache"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ejpain.2007.06.003","article-title":"Butterbur root extract and music therapy in the prevention of childhood migraine: an explorative study","volume":"12","author":"Oelkers-Ax","year":"2008","journal-title":"Eur J Pain"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1111\/bph.13917","article-title":"The anti-migraine component of butterbur extracts, isopetasin, desensitizes peptidergic nociceptors by acting on TRPA1 cation channel","volume":"174","author":"Benemei","year":"2017","journal-title":"Br J Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"864689","DOI":"10.3389\/fneur.2022.864689","article-title":"Petasites for migraine prevention: new data on mode of action, pharmacology and safety. A narrative review","volume":"13","author":"Borlak","year":"2022","journal-title":"Front Neurol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-021-01235-5","article-title":"Petasin and isopetasin reduce CGRP release from trigeminal afferents indicating an inhibitory effect on TRPA1 and TRPV1 receptor channels","volume":"22","author":"Kleeberg-Hartmann","year":"2021","journal-title":"J Headache Pain"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1440-1681.2009.05283.x","article-title":"Cellular calcium regulatory machinery of vasorelaxation elicited by petasina","volume":"37","author":"Wang","year":"2010","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The international classification of headache disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40122-024-00690-7","article-title":"The global burden of migraine: a 30-year trend review and future projections by age, sex, country, and region","volume":"14","author":"Dong","year":"2024","journal-title":"Pain Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","article-title":"Migraine: epidemiology, burden, and comorbidity","volume":"37","author":"Burch","year":"2019","journal-title":"Neurol Clin"},{"key":"ref20","first-page":"17","article-title":"Migraine headache prophylaxis","volume":"99","author":"Ha","year":"2019","journal-title":"Am Fam Physician"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e13002","DOI":"10.7759\/cureus.13002","article-title":"Comparing the efficacy, safety, and superiority of calcitonin gene-related peptide monoclonal antibodies and botox in preventing and treating migraines","volume":"13","author":"Siddiqui","year":"2021","journal-title":"Cureus"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-023-01594-1","article-title":"The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis","volume":"24","author":"Lampl","year":"2023","journal-title":"J Headache Pain"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1080\/00325481.2022.2080381","article-title":"Brazilian descriptive study of 104 consecutive real-world migraine patients treated with monoclonal antibodies","volume":"134","author":"Krymchantowski","year":"2022","journal-title":"Postgrad Med"},{"key":"ref24","first-page":"42","article-title":"Effectiveness of chemical, herbal and dietetic migraine prophylactic. An overview of randomized controlled double-blind studies","volume":"151","author":"Diener","year":"2009","journal-title":"MMW Fortschr Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1526-4610.2012.02185.x","article-title":"The 2012 AHS\/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines","volume":"52","author":"Loder","year":"2012","journal-title":"Headache"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1212\/WNL.0b013e3182535d0c","article-title":"Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults report of the quality standards Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"78","author":"Holland","year":"2012","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.18773\/austprescr.2020.047","article-title":"Migraine management","volume":"43","author":"Jenkins","year":"2020","journal-title":"Aust Prescr"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4103\/ijt.ijt_10_18","article-title":"Valproate: it\u2019s effects on hair","volume":"10","author":"Kakunje","year":"2018","journal-title":"Int J Trichology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/ene.13621","article-title":"Flunarizine in migraine-related headache prevention: results from 200 patients treated in the UK","volume":"25","author":"Karsan","year":"2018","journal-title":"Eur J Neurol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","article-title":"Adherence to oral migraine-preventive medications among patients with chronic migraine","volume":"35","author":"Hepp","year":"2015","journal-title":"Cephalalgia"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","article-title":"Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II)","volume":"53","author":"Blumenfeld","year":"2013","journal-title":"Headache"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/head.14430","article-title":"A qualitative evidence synthesis of patient perspectives on migraine treatment features and outcomes","volume":"63","author":"Urtecho","year":"2023","journal-title":"Headache"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1080\/14737175.2024.2365312","article-title":"Preferences and perceptions of 617 migraine patients on acute and preventive migraine treatment attributes and clinical trial endpoints","volume":"24","author":"Vikelis","year":"2024","journal-title":"Expert Rev Neurother"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.38212\/2224-6614.2743","article-title":"Pyrrolizidine alkaloids-tumorigenic components in Chinese herbal medicines and dietary supplements","volume":"10","author":"Fu","year":"2002","journal-title":"J Food Drug Anal"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/BTAT.S54023","article-title":"Update on the efficacy and safety of Petadolex\u00ae, a butterbur extract for migraine prophylaxis","volume":"4","author":"Prieto","year":"2014","journal-title":"Bot Targets Ther"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1046\/j.1526-4610.2003.03015.x","article-title":"Safety of a patented special butterbur root extract for migraine prevention","volume":"43","author":"Danesch","year":"2003","journal-title":"Headache"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/J157v05n03_12","article-title":"Butterbur: an evidence-based systematic review by the natural standard research collaboration","volume":"5","author":"Giles","year":"2005","journal-title":"J Herb Pharmacother"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ctcp.2012.04.003","article-title":"Butterbur extract: prophylactic treatment for childhood migraines","volume":"20","author":"Utterback","year":"2014","journal-title":"Complement Ther Clin Pract"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11940-016-0398-1","article-title":"Nutraceuticals in acute and prophylactic treatment of migraine","volume":"18","author":"Daniel","year":"2016","journal-title":"Curr Treat Options Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1784624\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:27:49Z","timestamp":1773293269000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1784624\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":39,"alternative-id":["10.3389\/fneur.2026.1784624"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1784624","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1784624"}}